|
KMID : 1144820190250040398
|
|
대한의생명과학회지
2019 Volume.25 No. 4 p.398 ~ p.406
|
|
|
Development of Genetically Modified Tumor Cell Containing Co-stimulatory Molecule
|
|
Kim Hong-Sung
|
|
|
Abstract
|
|
|
|
Cancer immunotherapy using gene-modified tumor cells is safe and customized cancer treatment method. In this study, we made gene-modified tumor cells by transferring costimulatory molecules, 4-1BBL and OX40L, into tumor cells using lentivirus vector, and identified anti-cancer effect of gene-modified tumor cells in CT26 mouse colorectal tumor model. We construct pLVX-puro-4-1BBL, -OX40L vector for lentivirus production and optimized the transfection efficiency and transduction efficiency. The transfection efficiency is maximal at DNA:cationic polymer = 1:0.5 and DNA 2 μg for lentivirus production. Then, the lentiviral including 4-1BBL and OX40L was used to deliver CT26 mouse tumor cells to establish optimal delivery conditions according to the amount of virus. The transduction efficiency is maximal at 500 μL volume of lentiviral stock without change in cell shape or growth rate. CT26-4-1BBL, CT26-OX40L significantly inhibited the tumor growth compare with CT26-WT or CT26-β-gal cell line. These data showed the possibility the use of genetically modified tumor cells with costimulatory molecule as cancer immunotherapy agent.
|
|
|
KEYWORD
|
|
|
Genetically modified tumor cell, Gene transfection, Transfection efficiency, Tumor growth pattern
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|